BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ubamatamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ubamatamab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03564340-2789@assetmemo.bio
DTSTAMP:20261121T005851Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Ubamatamab: Phase 1/2 readout est. (NCT03564340)
DESCRIPTION:Ubamatamab\, phase 1/2\, Ovarian Cancer.\nStudy: Study of REGN4
 018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in A
 dult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Ex
 pressing (MUC16+) Cancers\nEstimated primary completion: 10 May 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/ubamatamab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT03564340
URL:https://assetmemo.bio/drug/ubamatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06444880-2789@assetmemo.bio
DTSTAMP:20261121T005851Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ubamatamab: Phase 2 readout est. (NCT06444880)
DESCRIPTION:Ubamatamab\, phase 2.\nStudy: Phase II Trial of Ubamatamab Alon
 e or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient 
 Malignancies\nEstimated primary completion: 31 July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/ubamatamab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06444880
URL:https://assetmemo.bio/drug/ubamatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06787612-2789@assetmemo.bio
DTSTAMP:20261121T005851Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ubamatamab: Phase 2 readout est. (NCT06787612)
DESCRIPTION:Ubamatamab\, phase 2\, Ovarian Cancer.\nStudy: Investigation of
  Ubamatamab Combination Therapy in Adult Participants With Platinum-Resist
 ant Ovarian Cancer\nEstimated primary completion: 30 June 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ubamatamab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06787612
URL:https://assetmemo.bio/drug/ubamatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07637851-2789@assetmemo.bio
DTSTAMP:20261121T005851Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Ubamatamab: Phase 1/2 readout est. (NCT07637851)
DESCRIPTION:Ubamatamab\, phase 1/2\, Ovarian Cancer.\nStudy: Safety and Eff
 icacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer\nEstima
 ted primary completion: September 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ubamatamab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07637851
URL:https://assetmemo.bio/drug/ubamatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04590326-2789@assetmemo.bio
DTSTAMP:20261121T005851Z
DTSTART;VALUE=DATE:20281108
DTEND;VALUE=DATE:20281109
SUMMARY:Ubamatamab: Phase 1/2 readout est. (NCT04590326)
DESCRIPTION:Ubamatamab\, phase 1/2\, Ovarian Cancer.\nStudy: A Study to Fin
 d Out How Safe REGN5668 is and How Well it Works In Adult Women When Given
  With Either Cemiplimab\, or Cemiplimab + Fianlimab\, or Ubamatamab\nEstim
 ated primary completion: 8 November 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ubamatamab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04590326
URL:https://assetmemo.bio/drug/ubamatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154290-2789@assetmemo.bio
DTSTAMP:20261121T005851Z
DTSTART;VALUE=DATE:20300610
DTEND;VALUE=DATE:20300611
SUMMARY:Ubamatamab: Phase 2 readout est. (NCT07154290)
DESCRIPTION:Ubamatamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Ad
 ult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCL
 C)\nEstimated primary completion: 10 June 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ubamatamab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07154290
URL:https://assetmemo.bio/drug/ubamatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
